Andrew M. Lowy

Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy.

Neoadjuvant therapy for pancreatic cancer.

Beyond the ivory tower: outcomes following surgery for ampullary cancer.

Case report: focal nesidioblastosis ("nesidioblastoma") in an adult.

Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.

Pancreatic cancer: preface.

Cystic neoplasms of the pancreas.

The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells.

Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.

Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.

The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.

Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.

Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer.

Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Therapeutic advances in pancreatic cancer.

A dual-color genetically engineered mouse model for multispectral imaging of the pancreatic microenvironment.

PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes.

Improved perioperative outcomes with minimally invasive distal pancreatectomy: results from a population-based analysis.

Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor.

The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Single-incision laparoscopic surgery through an ostomy site: a natural approach by an unnatural orifice.

An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).

Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Borderline resectable pancreatic cancer: definitions and management.

Long-term outcomes after total pancreatectomy and islet cell autotransplantation: is it a durable operation?

Correction: Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.

A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.

Enteral stenting for gastric outlet obstruction and afferent limb syndrome following pancreaticoduodenectomy.

Tumor-penetrating iRGD peptide inhibits metastasis.

Laparoscopic evacuation of mucinous ascites for palliation of pseudomyxoma peritonei.

Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.

Approach to patients with pancreatic cancer without detectable metastases.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.

Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery.

A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.

Urokinase-controlled tumor penetrating peptide.

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.

Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis.

Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care.

Molecular Pathways: Targeting the Microenvironment of Liver Metastases.

An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).

Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.

GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells.

Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy.

Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.

Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients.

GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets.

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.

E47 Governs the MYC-CDKN1B/p27-RB Network to Growth Arrest PDA Cells Independent of CDKN2A/p16 and Wild-Type p53.

Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?

Exosomes from Pancreatic Juice: A Step Closer to the Holy Grail?

Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53.

A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma.

MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study.

Incidence, Risk Factors, and Prevention Strategies for Venous Thromboembolism after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Obstruction-Free Survival Following Operative Intervention for Malignant Bowel Obstruction in Appendiceal Cancer.

Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative.

Association of an acute pain service with postoperative outcomes following pancreaticoduodenectomy.

Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.

Detection and Quantification of GPCR mRNA: An Assessment and Implications of Data from High-Content Methods.

Adherence with operative standards in the treatment of gastric cancer in the United States.

Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways.

Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.

Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.

Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms.

A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer.

Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness.

Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer.

Clinical Data Prediction Model to Identify Patients With Early-Stage Pancreatic Cancer.

Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis.

Tumor-penetrating therapy for β5 integrin-rich pancreas cancer.

Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC.

Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC).

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.

Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond.

Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies.

Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft.

The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.

Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test.

An Ex Vivo Organotypic Culture Platform for Functional Interrogation of Human Appendiceal Cancer Reveals a Prominent and Heterogenous Immunological Landscape.

Alvimopan for Enhanced Gastrointestinal Recovery after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Randomized Controlled Trial.

Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome.

Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?

ASO Visual Abstract: Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?

Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis.